Phase 3 N=243 Dysport® Adult Upper Limb Spasticity
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Assesment of Post-stroke Elbow Flexor Spasticity in Different Forearm Positions
Post-stroke Elbow Spasticity
Primary: Dynamic Component of Spasticity (Spasticity Angle) — 70; 60; 57.5 degree — p=<0.001
Phase 3 N=109 Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups…
N/A N=4 Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity
Spasticity
Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts
Phase 3 N=192 IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
Upper Limb Spasticity
Primary: Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set — 51; 44 participants
N/A N=108 Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
Muscle Spasticity
Primary: Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Elbow at Baseline — 2; 6; 18; 39 Participants
N/A N=19 Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device
Upper Limb Spasticity
Primary: Decrease in Pain and Symptoms Caused by Hypertonia in the Upper Arm as Measured by an Improvement of 1 Point or Greater on the Modified Ashworth Scale (MAS) at Day 7…
Phase 3 N=235 BOTOX® Treatment in Pediatric Upper Limb Spasticity
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of the Principal Muscle Group at Weeks 4 and 6 — -1.87; -1.92; -1.21 score on a scale…
Phase 3 N=317 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
Post-stroke Spasticity of the Upper Limb
Primary: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern — -0.9; -0.5 units on a scale — p=<0.001
Phase 2 N=83 Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
Upper Limb Spasticity
Primary: Change From Baseline at Week 6 on the Modified Ashworth Scale (MAS) in the Suprahypertonic Muscle Group (SMG) Score — -0.9; -1.0; -1.5; -0.8 score on a scale — p=0.7645
Phase 3 N=258 Dysport® Adult Upper Limb Spasticity Extension Study
Nervous System Disorders
Primary: Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 102; 62; 47; 11 Participants
N/A N=231 Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
Multiple Sclerosis
Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale
Phase 4 N=42 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
Stroke · Upper Limb Spasticity
Primary: Time Between the Initial Injection and the Appearance of Reinjection Criteria as Evaluated by the Modified Ashworth Scale (MAS) and Spasticity Symptoms — 156; 32 days…
Phase 3 N=220 BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE) — 58.7 percentage of participants
Phase 4 N=60 SISTERS: Spasticity In Stroke Study - Randomized Study
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
Phase 3 N=388 Dysport® Adult Lower Limb Spasticity Study
Leg Spasticity
Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…
Phase 3 N=109 A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
Spasticity, Post-Stroke
Primary: Change From Baseline at Week 6 and Week 12 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) — -1.21; -1.33; -0.88; -1.12 scores on a scale…
Phase 3 N=351 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Cerebral Palsy · Spasticity
Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017
Phase 3 N=212 Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Primary: Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMG — -1.5; -1.9; -2.2 score on a scale — p=0.0118
Phase 2 N=26 The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
Stroke · Cerebrovascular Accident (CVA) · Hemiparesis
Primary: Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed — 13.678; -8.783; 15.927…
Phase 3 N=468 BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Muscle Spasticity
Primary: Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale — 4.1; 4.1; -0.81; -0.61 Scores on a Scale
N/A N=18 Spinal Cord Stimulation to Augment Activity Based Therapy
Transcutaneous Spinal Stimulation · Walking · Spasticity
Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second
N/A N=14 Passive Tactile Stimulation for Stroke Rehabilitation
Stroke · Stroke, Ischemic · Stroke Hemorrhagic
Primary: Change in Modified Ashworth at 12 Weeks — 1.1 units on a scale — p=0.00025
Phase 4 N=274 BOTOX® Economic Spasticity Trial (BEST)
Muscle Spasticity
Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients
Phase 4 N=64 A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
Secondary Progressive Multiple Sclerosis · Primary Progressive Multiple Sclerosis
Primary: Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT) — 4; 3; 58; 59 Participants
Phase 3 N=196 MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
Spasticity
Primary: MAS(Modified Ashworth Scale) of Wrist Flexor — 2.41; 2.52; 1.02; 0.96 Scores on a MAS Scale — p=0.1347
Phase 3 N=155 Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Primary: Occurrence of Treatment-Emergent Adverse Events (AEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs) by Injection Cycle, Overall and Related to the…
N/A N=96 Multimodal Treatment for Hemiplegic Shoulder Pain
Stroke · Shoulder Pain
Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) - Mean Change From Baseline — 7.1; 7.4; 8.1; -2.8 units on a scale
N/A N=31 Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity
Upper Limb Spasticity
Primary: The Maximum Change in Fugl-Meyer Upper Extremity Score From the Baseline Exam to Any Post Injection Visit in Each Treatment Arm. Comparison of the Difference Scores…
Phase 3 N=345 Dysport® Adult Lower Limb Spasticity Follow-on Study
Post-stroke Spasticity · Spasticity Post-Traumatic Brain Injury
Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants